The economic burden of rheumatoid arthritis in a developing nation: Results from a one-year prospective cohort study in Thailand

Journal of Rheumatology

Volumn 34, Issue 1, 2007, Pages 57-63

  Osiri, Manathip ^a   Maetzel, Andreas ^a,b,c   Tugwell, Peter ^a,d  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b UNIVERSITY OF TORONTO   (Canada)

^c AMGEN INC   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Burden of illness; Cost analysis; Disability; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; NON PRESCRIPTION DRUG; PREDNISOLONE;

ADULT; AGED; ALTERNATIVE MEDICINE; ARTHRITIS; ARTICLE; COHORT ANALYSIS; DEVELOPING COUNTRY; DISABILITY; DISEASE ACTIVITY; ECONOMIC ASPECT; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSIOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RATING SCALE; RHEUMATOID ARTHRITIS; THAILAND;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; COHORT STUDIES; COST OF ILLNESS; COSTS AND COST ANALYSIS; DEVELOPING COUNTRIES; FEMALE; HUMANS; LIFE STYLE; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; THAILAND;

EID: 33846216464     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000;29:305-20.
2. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology Oxford 2000;39:28-33.
3. Markenson JA. Worldwide trends in the socioeconomic impact and long-tern prognosis of rheumatoid arthritis. Semin Arthritis Rheum 1991;21 Suppl 1:4-12.
4. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22 Suppl 1:1-12.
5. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: work disability: a prospective 18-year study of 823 patients. J Rheumatol 1998;25:2108-17.
6. Meenan RF, Yelin EH, Nevitt M, Epstein WV. The impact of chronic disease. A sociomedical profile of rheumatoid arthritis. Arthritis Rheum 1981;24:544-9.
7. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986;29:488-93.
8. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis. The impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-18.
9. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:2750-62.
10. Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum 1978;21:827-33.
11. van Jaarsveld CH, Jacobs JW, Schrijvers AJ, van Albada-Kuipers GA, Hofman DM, Bijlsma JW. Effects of rheumatoid arthritis on employment and social participation during the first years of disease in The Netherlands. Br J Rheumatol 1998;37:848-53.
12. Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999;26:1681-5.
13. Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001;44:528-34.
14. Newhall-Perry K, Law NJ, Ramos B, Sterz M, Wong WK. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. J Rheumatol 2000;27:1156-63.
15. WHO Scientific Group. The burden of musculoskeletal conditions at the start of the new millennium. WHO Technical Report Series 919. Geneva: World Health Organization; 2003.
16. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646-56.
17. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:15-24.
18. Ministry of Public Health, Thailand. Health welfare card for those with low income [Internet]. Available at: http://www.moph.go.th
19. Ministry of Public Health, Thailand. Universal Coverage System of the health of Thai people [Internet]. Available at: http://www.moph.go.th http://ict.moph.go.th/modern/
20. Department of Social Development and Welfare. Ministry of Social Development and Human Security, Thailand. Capacity Rehabilitation for the Disabled, Act of Parliament, B.E. 2534. Available at: http://www.dsdw.go.th
21. Osiri M, Deesomchok U, Tugwell P. Evaluation of functional ability of Thai patients with rheumatoid arthritis by the use of a Thai version of the Health Assessment Questionnaire. Rheumatology Oxford 2001;40:555-8.
22. Kamolratanakul P, Sriratanaban J, Ngamkiatpaisan S. Cost analysis of patient services in King Chulalongkorn Memorial Hospital: Patients services areas. Reports for King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, August 2001.
23. Heston A, Summers R, Aten B. Penn World Table version 6.1. Center for International Comparisons at the University of Pennsylvania (CICUP). October 2002 [Internet]. Available at: http://pwt.econ.upenn.edu
24. Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395-401.
25. Lajas C, Abasolo L, Bellajdel B, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003;49:64-70.
26. Jonsson B, Larsson S-E. Functional improvement and costs of hip and knee arthroplasty in destructive rheumatoid arthritis. Scand J Rheumatol 1991;20:351-7.
27. Clarke A, Zowall H, Levinton C, et al. Direct and indirect medical costs incurred by Canadian patients with RA: a 12 year study. J Rheumatol 1997;24:1051-60.
28. Ministry of Public Health. 2001 budget of the Ministry of Public Health of Thailand [Internet]. Available from: http://www.moph.go.th
29. Chaiamnuay P, Darmawan J, Muirden KD, Assawatanabodee P. Epidemiology of rheumatic disease in rural Thailand: a WHO-ILAR COPCORD study. Community Oriented Programme for the Control of Rheumatic Disease. J Rheumatol 1998;25:1382-7.
30. Ollendorf DA, Peterson AN, Doyle J, Huse DM. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. Am J Manag Care 2002;8 Suppl 7:5203-13.
31. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol 2002;29:1156-65.
32. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology Oxford 2003;42:326-35.
33. Welsing PM, Severens JL, Hartman M, van Riel PL, Laan RF. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in The Netherlands. Arthritis Rheum 2004;51:964-73.
34. Wong JB, Singh G, Kavanaugh A. Estimating the cost effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
35. National Economic and Social Development Board, Office of the Prime Minister. Thailand's economic status for the year 2001 [Internet]. Available at: http://www.nesdb.go.th
36. Dai SM, Han XH, Zhao DB, Shi YQ, Liu Y, Meng JM. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study. J Rheumatol 2003;30:2245-51.
37. Minh Hoa TT, Darmawan J, Chen SL, et al. Prevalence of the rheumatic diseases in urban Vietnam: a WHO-ILAR COPCORD study. J Rheumatol 2003;30:2252-6.